CCM
GILD icon

Copernicus Capital Management’s Gilead Sciences GILD Stock Holding History

Copernicus Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-197,916
Closed -$12.5M – 19
2019
Q3 		$12.5M Buy
197,916
+50,000
+34% +$3.27M 11.67% 1
2019
Q2 		$9.99M Buy
147,916
+106,970
+261% +$7.04M 8.89% 7
2019
Q1 		$2.66M Sell
40,946
-58,054
-59% -$3.86M 6.83% 9
2018
Q4 		$6.19M Buy
+99,000
New +$6.92M 11.66% 2
2018
Q2 		– Sell
-116,506
Closed -$8.78M – 22
2018
Q1 		$8.78M Buy
+116,506
New +$9.26M 7% 6

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Copernicus Capital Management's GILD Position: Q4 2019 in Review

Copernicus Capital Management sold out of Gilead Sciences (GILD) in Q4 2019, closing a stake of 197,916 shares — an estimated $12.5M sold.

Copernicus Capital Management first reported a position in GILD in Q1 2018 and held it in 5 quarters. The position peaked at $12.5M in Q3 2019. 1,555 funds tracked by Wall St. Rank hold GILD as of Q4 2019.

  • Copernicus Capital Management reported no remaining Gilead Sciences position as of Q4 2019 after selling out during the quarter.
  • Copernicus Capital Management sold 197,916 Gilead Sciences shares in Q4 2019, an estimated $12.5M.
  • Copernicus Capital Management first reported a position in Gilead Sciences in Q1 2018 and held it in 5 quarters.
  • Copernicus Capital Management's Gilead Sciences position peaked at $12.5M in Q3 2019.
  • 1,555 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2019.

Based on Copernicus Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.